

KOS Diagnostic Lab

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. S.C MEHTA

AGE/ GENDER : 77 YRS/MALE **PATIENT ID** : 1598315

COLLECTED BY: SURJESH REG. NO./LAB NO. : 012409010011

 REFERRED BY
 :
 REGISTRATION DATE
 : 01/Sep/2024 09:00 AM

 BARCODE NO.
 : 01516082
 COLLECTION DATE
 : 01/Sep/2024 09:22AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 01/Sep/2024 10:58AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE: BASIC

CHOLESTEROL TOTAL: SERUM 154.78 mg/dL OPTIMAL: < 200.0

by CHOLESTEROL OXIDASE PAP

BORDERLINE HIGH: 200.0 - 239.0

HIGH CHOLESTEROL: > OR = 240.0

TRIGLYCERIDES: SERUM 173.87^H mg/dL OPTIMAL: < 150.0

by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

BORDERLINE HIGH: 150.0 - 199.0

HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM 46.82 mg/dL LOW HDL: < 30.0

by SELECTIVE INHIBITION BORDERLINE HIG

BORDERLINE HIGH HDL: 30.0 -

60.0

by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 100.0 - 129.0

DODDEDLINE LICH. 120.0 - 127.0

BORDERLINE HIGH: 130.0 - 159.0

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM 107.96 mg/dL OPTIMAL: < 130.0

by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 130.0 - 159.0

BORDERLINE HIGH: 160.0 - 189.0

HIGH: 190.0 - 219.0

VERY HIGH: > OR = 220.0

VLDL CHOLESTEROL: SERUM 34.77 mg/dL 0.00 - 45.00 by CALCULATED, SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM 483.43 mg/dL 350.00 - 700.00

by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM

3.31

RATIO

LOW RISK: 3.30 - 4.40

AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0

HIGH RISK: > 11.0

LDL/HDL RATIO: SERUM 1.56 RATIO LOW RISK: 0.50 - 3.0



by CALCULATED, SPECTROPHOTOMETRY

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)





KOS Diagnostic Lab

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. S.C MEHTA

AGE/ GENDER : 77 YRS/MALE PATIENT ID : 1598315

COLLECTED BY : SURJESH REG. NO./LAB NO. : 012409010011

 REFERRED BY
 :
 REGISTRATION DATE
 : 01/Sep/2024 09:00 AM

 BARCODE NO.
 : 01516082
 COLLECTION DATE
 : 01/Sep/2024 09:22AM

CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 01/Sep/2024 10:58AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval
by CALCULATED, SPECTROPHOTOMETRY			MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.71	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

*** End Of Report ***



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

